Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML)

Yasuyoshi Morita, Takayuki Ikezoe, MD PhD, Kiyoshi Ando, Masahiro Onozawa, Takahisa Yamane, MD PhD, Naoko Hosono, MD PhD, Toru Kiguchi, Hiromi Iwasaki, Toshihiro Miyamoto, MD PhD, Miho Kasai, Saori Sugimoto, Yasushi Miyazaki, MD PhD, Masahiro Kizaki, MD, Koichi Akashi, MD PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134078

Published: 2020

Journal Articles

Platelet Decrease and Efficacy of Platelet-Rich Plasma Return for Peripheral Blood Stem Cell Apheresis

Takahiro Shima, MD PhD, Teppei Sakoda, MD, Tomoko Henzan, MD, Yuya Kunisaki, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD, Toshihiro Miyamoto, MD PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142316

Published: 2020

Journal Articles

Nilotinib Vs. Dasatinib in Achieving MR 4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-134168

Published: 2020

Journal Articles

ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study

Hitoshi Hanamoto, Yasuyoshi Morita, Motoshi Ichikawa, Yasuhito Nannya, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD, Tomoko Hata, Toshihiro Miyamoto, MD PhD, Hiroshi Kawabata, MD PhD, Kazuto Takeuchi, Hiroko Tanaka, Junji Kishimoto, Satoru Miyano, PhD, Itaru Matsumura, MDPhD, Seishi Ogawa, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD, Kinuko Mitani

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134483

Published: 2020

Journal Articles

Identification of Thrombospondin-1 As a Novel Substrate of Cereblon Responsible for IMiDs-Induced Venous Thromboembolism

Kiwamu Hatakeyama, MD, Yoshikane Kikushige, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 631.

https://doi.org/10.1182/blood-2019-125670

Published: 2019

Journal Articles

Graft-Versus-Host Disease-Free, Relapse-Free Survival in Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma Provides a Novel Donor Selection Paradigm

Hiroyuki Muranushi, MD, Takero Shindo, MD PhD, Masakatsu Hishizawa, MD PhD, Masahito Tokunaga, MD PhD, Atsushi Wake, MD PhD, Nobuaki Nakano, MD, Tetsuya Eto, MD PhD, Michihiro Hidaka, MD PhD, Ilseung Choi, MD PhD, Toshihiro Miyamoto, MD PhD, Naoyuki Uchida, MD PhD, Yukiyoshi Moriuchi, MD, Yasuhiko Miyazaki, MD PhD, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, MD PhD, Koji Kato, MD PhD

Blood (2019) 134 (Supplement_1): 2008.

https://doi.org/10.1182/blood-2019-123318

Published: 2019

Journal Articles

Identification of GPAT1 As a Novel Therapeutic Target for Acute Leukemia By Inhibiting Leukemia Specific Metabolism

Hidetoshi Irifune, MD, Yu Kochi, MD, Masayasu Hayashi, MD PhD, Yoshikane Kikushige, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 1384.

https://doi.org/10.1182/blood-2019-125661

Published: 2019

Journal Articles

Human Acute Leukemia Is Addicted to Branched-Chain Amino Acid Metabolism to Maintain Leukemia Stemness

Yoshikane Kikushige, MD PhD, Toshihiro Miyamoto, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 2516.

https://doi.org/10.1182/blood-2019-129372

Published: 2019

Journal Articles

A Fast and Accurate Diagnostic Method for Ph-like ALL Using the Ncounter System

Kensuke Sasaki, MD, Kohta Miyawaki, MD PhD, Yuichiro Semba, MD PhD, Koji Kato, MD PhD, Jumpei Nogami, PhD, Takeshi Sugio, MD PhD, Toshihiro Miyamoto, MD PhD, Yoshikiyo Ito, MD PhD, Koji Nagafuji, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 375.

https://doi.org/10.1182/blood-2019-129625

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Yukio Kobayashi, Iekuni Oh, MD PhD, Toshihiro Miyamoto, MD PhD, Won-Sik Lee, Hiroatsu Iida, MD PhD, Hironobu Minami, MD PhD, Yoshinobu Maeda, MD PhD, Jun Ho Jang, Sung-Soo Yoon, MD PhD, Su-Peng Yeh, MD, Qui Tran, Joan Morris, Janet L. Franklin, Ka-Wing Chong, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 5069.

https://doi.org/10.1182/blood-2019-124582

Published: 2019

Journal Articles

Evaluation of TIM-3-Positive LSCs Post Allo-SCT Is a Highly Sensitive Strategy to Predict AML Relapses

Teppei Sakoda, MD, Yoshikane Kikushige, MD PhD, Takuya Harada, MD, Hidetoshi Irifune, MD, Masayasu Hayashi, MD PhD, Goichi Yoshimoto, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 2702.

https://doi.org/10.1182/blood-2019-127779

Published: 2019

Journal Articles

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

Masayasu Hayashi, MD PhD, Yoshikane Kikushige, MD PhD, Takuya Harada, MD, Toshihiro Miyamoto, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 910.

https://doi.org/10.1182/blood-2019-130694

Published: 2019

Journal Articles

Minimal Residual Disease (MRD) Status after Induction Therapy Is a Strong Prognostic Factor in the Treatment of Adult Ph (-) Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Study (ALL MRD2008 Study)

Koji Nagafuji, MD PhD, Toshihiro Miyamoto, MD PhD, Tetsuya Eto, MD PhD, Ryosuke Ogawa, MD PhD, Naoyuki Uchida, MD PhD, Ken Takase, MD, Noriaki Kawano, MD PhD, Tomoaki Fujisaki, MD PhD, Tomohiko Kamimura, MD PhD, Atsushi Wake, MD PhD, Hirokazu Okumura, MD PhD, Yasuhiko Miyazaki, MD PhD, Yasushi Takamatsu, MD PhD, Toshiro Kurokawa, MD PhD, Yuju Ohno, MD PhD, Shouhei Yokota, MP.Path, Koichi Akashi, MD PhD

Blood (2018) 132 (Supplement 1): 3970.

https://doi.org/10.1182/blood-2018-99-112848

Published: 2018

Journal Articles

Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Yukio Kobayashi, MD DSc, Zachary F. Zimmerman, Iekuni Oh, MD PhD, Yoshinobu Maeda, MD PhD, Hironobu Minami, MD PhD, Toshihiro Miyamoto, MD PhD, Toru Sakura, PhD MD, Hiroatsu Iida, MD PhD, Yuqi Chen, PhD, Hitoshi Kiyoi, MD PhD

Blood (2018) 132 (Supplement 1): 5167.

https://doi.org/10.1182/blood-2018-99-112584

Published: 2018

Journal Articles

CPSF1-Mediated Acute Myeloid Leukemia Fusion 3'UTR Alternation Is a Potential Therapeutic Target

Takahiro Shima, MD PhD, Amanda G Davis, Daniel T Johnson, Yu Kochi, MD, Sayuri Miyauchi, DDS, PhD, Samuel A Stoner, Junichiro Yuda, MD, Toshihiro Miyamoto, MD PhD, Jie-Hua Zhou, MD, Edward D. Ball, MD, Koichi Akashi, MD PhD, Dong-Er Zhang, PhD

Blood (2018) 132 (Supplement 1): 885.

https://doi.org/10.1182/blood-2018-99-119199

Published: 2018

Journal Articles

Mixed Chimerism and Secondary Engraftment Failure in Allogeneic Transplantation for Aplastic Anemia

Shinichi Kako, MD, Hirohito Yamazaki, MD PhD, Kazuteru Ohashi, MD PhD, Yukiyasu Ozawa, MD PhD, Shuichi Ota, MD, Yoshinobu Kanda, MD PhD, Tetsuo Maeda, MD, Jun Kato, MD, Ken Ishiyama, MD PhD, Ken-Ichi Matsuoka, MD PhD, Toshihiro Miyamoto, MD PhD, Takahiro Fukuda, MD PhD, Tatsuo Ichinohe, MD PhD, Yoshiko Atsuta, MD PhD, Takehiko Mori, MD PhD

Blood (2018) 132 (Supplement 1): 4631.

https://doi.org/10.1182/blood-2018-99-111175

Published: 2018

Journal Articles

Who Is the Best Donor for the Second Transplant?: HLA Discrepancy between Graft and Host Rather Than That Graft and First Donor May Impact the Second Transplant Outcome from the JSHCT

Yoshinobu Maeda, MD PhD, Tomotaka Ugai, MD, Eisei Kondo, Kazuhiro Ikegame, MD PhD, Makoto Murata, MD PhD, Naoyuki Uchida, MD PhD, Toshihiro Miyamoto, MD PhD, Satoshi Takahashi, MD PhD, Kazuteru Ohashi, MD PhD, Hirohisa Nakamae, MD PhD, Makoto Hirokawa, MD PhD, Tatsuo Ichinohe, MD PhD, Yoshiko Atsuta, MD PhD, Yoshinobu Kanda, MD PhD, Junya Kanda, MD

Blood (2018) 132 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2018-99-112796

Published: 2018

Journal Articles

Evaluation of TIM-3+ LSCs Is a Highly Sensitive MRD Monitoring Strategy to Predict AML Relapse after Allogenic Stem Cell Transplantation

Masayasu Hayashi, MD PhD, Teppei Sakoda, MD, Yoshikane Kikushige, MD PhD, Hidetoshi Irifune, MD, Goichi Yoshimoto, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2018) 132 (Supplement 1): 1390.

https://doi.org/10.1182/blood-2018-99-116640

Published: 2018

Journal Articles

Identification of TIM-3/Gal-9 Autocrine Loop As a Novel Wnt-Ligands Independent Machinery for the Constitutive Activation of Canonical Wnt Pathway in AML-LSCs

Teppei Sakoda, MD, Yoshikane Kikushige, MD PhD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2018) 132 (Supplement 1): 1460.

https://doi.org/10.1182/blood-2018-99-116897

Published: 2018

NARROW

Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML)

Platelet Decrease and Efficacy of Platelet-Rich Plasma Return for Peripheral Blood Stem Cell Apheresis

Nilotinib Vs. Dasatinib in Achieving MR 4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212

ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study

Identification of Thrombospondin-1 As a Novel Substrate of Cereblon Responsible for IMiDs-Induced Venous Thromboembolism

Graft-Versus-Host Disease-Free, Relapse-Free Survival in Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma Provides a Novel Donor Selection Paradigm

Identification of GPAT1 As a Novel Therapeutic Target for Acute Leukemia By Inhibiting Leukemia Specific Metabolism

Human Acute Leukemia Is Addicted to Branched-Chain Amino Acid Metabolism to Maintain Leukemia Stemness

A Fast and Accurate Diagnostic Method for Ph-like ALL Using the Ncounter System

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Efficacy and Safety of Blinatumomab in Asian Adults with Relapsed/Refractory B-Precursor ALL

Evaluation of TIM-3-Positive LSCs Post Allo-SCT Is a Highly Sensitive Strategy to Predict AML Relapses

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

Minimal Residual Disease (MRD) Status after Induction Therapy Is a Strong Prognostic Factor in the Treatment of Adult Ph (-) Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Study (ALL MRD2008 Study)

Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

CPSF1-Mediated Acute Myeloid Leukemia Fusion 3'UTR Alternation Is a Potential Therapeutic Target

Mixed Chimerism and Secondary Engraftment Failure in Allogeneic Transplantation for Aplastic Anemia

Who Is the Best Donor for the Second Transplant?: HLA Discrepancy between Graft and Host Rather Than That Graft and First Donor May Impact the Second Transplant Outcome from the JSHCT

Evaluation of TIM-3+ LSCs Is a Highly Sensitive MRD Monitoring Strategy to Predict AML Relapse after Allogenic Stem Cell Transplantation

Identification of TIM-3/Gal-9 Autocrine Loop As a Novel Wnt-Ligands Independent Machinery for the Constitutive Activation of Canonical Wnt Pathway in AML-LSCs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only